Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	151	222	150	127	206	148
Short-Term Investments	479	759	828	632	803	351
Cash & Short-Term Investments	630	981	978	759	1,009	499
Cash Growth	-24.19%	0.31%	28.85%	-24.78%	102.20%	-31.52%
Accounts Receivable	18	11	20	38	39	745
Other Receivables	5	5	5	4	4	2
Receivables	23	16	25	42	43	747
Prepaid Expenses	11	10	13	30	15	16
Total Current Assets	664	1,007	1,016	831	1,067	1,262
Property, Plant & Equipment	33	98	112	143	135	137
Long-Term Investments	64	29	14	107	129	182
Other Long-Term Assets	57	5	8	14	14	11
Total Assets	818	1,139	1,150	1,095	1,345	1,592

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	44	42	18	17	20	10
Accrued Expenses	115	122	96	62	70	47
Current Portion of Leases	14	13	12	11	3	-
Current Income Taxes Payable	1	1	1	-	-	2
Current Unearned Revenue	14	35	85	91	97	102
Other Current Liabilities	11	18	14	3	3	5
Total Current Liabilities	199	231	226	184	193	166
Long-Term Debt	227	120	69	19	-	-
Long-Term Leases	-	86	99	110	117	117
Long-Term Unearned Revenue	34	43	234	307	355	462
Other Long-Term Liabilities	-	28	37	13	23	5
Total Liabilities	460	508	665	633	688	750

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	2,192	2,116	1,617	1,311	1,206	1,118
Retained Earnings	-1,832	-1,485	-1,132	-849	-542	-275
Comprehensive Income & Other	-2	-	-	-	-7	-1
Total Common Equity	358	631	485	462	657	842
Shareholders' Equity	358	631	485	462	657	842
Total Liabilities & Equity	818	1,139	1,150	1,095	1,345	1,592

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	241	219	180	140	120	117
Net Cash (Debt)	453	791	812	726	1,018	564
Net Cash Growth	-36.11%	-2.59%	11.85%	-28.68%	80.50%	-20.94%
Net Cash Per Share	3.64	7.36	9.01	9.81	14.14	7.62
Filing Date Shares Outstanding	143.99	125.35	105.84	90.86	73.01	71.06
Total Common Shares Outstanding	127.6	125.3	92.2	75.5	72.9	70.78
Working Capital	465	776	790	647	874	1,096
Book Value Per Share	2.81	5.04	5.26	6.12	9.01	11.90
Tangible Book Value	358	631	485	462	657	842
Tangible Book Value Per Share	2.81	5.04	5.26	6.12	9.01	11.90
Machinery	-	32	31	27	20	16
Construction In Progress	-	1	1	1	4	2
Leasehold Improvements	-	57	56	54	34	32

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Nov 4, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 10, 2026

Data Sources Report a data error